TCG Crossover Management, LLC — 13F Holdings & Portfolio
CIK 1839948 · latest 13F-HR filed 2026-05-15
TCG Crossover Management, LLC manages $3.50B in 13F-reported U.S. long-equity assets across 49 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are ABVX (20.65%), CGON (7.11%), TNGX (6.30%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 11 new positions, exited 5, added to 19, and trimmed 17.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$3.50B
Long-equity book
49
Distinct positions
2026-03-31
Filed 2026-05-15
+11 / −5 / ↑19 / ↓17
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- TANGO THERAPEUTICS INC$107.2M +94.8%
- CG ONCOLOGY INC$96.0M +63.0%
- MIRUM PHARMACEUTICALS INC$93.2M +1901.8%
- DIANTHUS THERAPEUTICS INC$71.6M +103.6%
- IMMUNOVANT INC$68.5M +162.3%
Top Trims
- ABIVAX SA AMERICAN DEPOSITARY SHARES-$237.4M -24.8%
- STRUCTURE THERAPEUTICS INC-$57.3M -89.4%
- OCULAR THERAPEUTIX INC-$55.7M -80.0%
- LIQUIDIA TECHNOLOGIES INC-$43.8M -74.2%
- FULCRUM THERAPEUTICS INC-$19.1M -32.2%
New Positions
- BIOCRYST PHARMACEUTICALS INC$104.9M
- VOR BIOPHARMA INC$96.5M
- DISC MEDICINE INC$85.8M
- SURROZEN INC$42.9M
- CENTURY THERAPEUTICS INC$39.0M
Exited Positions
- RAPT THERAPEUTICS INC$87.5M
- EYEPOINT PHARMACEUTICALS INC$65.3M
- AGIOS PHARMACEUTICALS INC$32.2M
- MAZE THERAPEUTICS INC$7.2M
- VENTYX BIOSCIENCES INC$2.9M
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | ABIVAX SA AMERICAN DEPOSITARY SHARES | ABVX | 00370M103 | $721.7M | 20.65% | 6,481,085 | SH |
| 2 | CG ONCOLOGY INC | CGON | 156944100 | $248.4M | 7.11% | 3,670,206 | SH |
| 3 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $220.3M | 6.30% | 10,531,071 | SH |
| 4 | COGENT BIOSCIENCES INC | COGT | 19240Q201 | $190.4M | 5.45% | 4,946,894 | SH |
| 5 | CENTESSA PHARMACEUTICALS PLC | CNTA | 152309100 | $170.3M | 4.87% | 4,286,480 | SH |
| 6 | DIANTHUS THERAPEUTICS INC | DNTH | 252828108 | $140.7M | 4.03% | 1,676,624 | SH |
| 7 | TYRA BIOSCIENCES INC | TYRA | 90240B106 | $124.4M | 3.56% | 3,248,980 | SH |
| 8 | IMMUNOVANT INC | IMVT | 45258J102 | $110.7M | 3.17% | 4,457,988 | SH |
| 9 | BIOCRYST PHARMACEUTICALS INC | BCRX | 09058V103 | $104.9M | 3.00% | 11,020,968 | SH |
| 10 | MIRUM PHARMACEUTICALS INC | MIRM | 604749101 | $98.1M | 2.81% | 1,062,049 | SH |
| 11 | VOR BIOPHARMA INC | VOR | 929033207 | $96.5M | 2.76% | 5,673,078 | SH |
| 12 | SPYRE THERAPEUTICS INC | SYRE | 00773J202 | $95.9M | 2.74% | 1,900,582 | SH |
| 13 | AMYLYX PHARMACEUTICALS INC | AMLX | 03237H101 | $86.8M | 2.48% | 6,243,812 | SH |
| 14 | DISC MEDICINE INC | IRON | 254604101 | $85.8M | 2.45% | 1,341,862 | SH |
| 15 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $83.7M | 2.39% | 4,615,144 | SH |
| 16 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $76.0M | 2.18% | 4,622,151 | SH |
| 17 | SAVARA INC | SVRA | 805111101 | $67.5M | 1.93% | 12,362,205 | SH |
| 18 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $56.1M | 1.60% | 576,473 | SH |
| 19 | KODIAK SCIENCES INC | KOD | 50015M109 | $55.1M | 1.58% | 1,445,538 | SH |
| 20 | LB PHARMACEUTICALS INC | LBRX | 50180M108 | $45.3M | 1.30% | 1,839,489 | SH |
| 21 | SURROZEN INC | SRZN | 86889P208 | $42.9M | 1.23% | 1,473,101 | SH |
| 22 | ADC THERAPEUTICS SA | ADCT | H0036K147 | $42.7M | 1.22% | 11,390,175 | SH |
| 23 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $42.5M | 1.22% | 4,273,356 | SH |
| 24 | FULCRUM THERAPEUTICS INC | FULC | 359616109 | $40.3M | 1.15% | 5,250,000 | SH |
| 25 | BIOHAVEN LTD | BHVN | G1110E107 | $39.2M | 1.12% | 4,631,317 | SH |
| 26 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $39.0M | 1.12% | 17,754,430 | SH |
| 27 | TECTONIC THERAPEUTIC INC | TECX | 878972108 | $37.2M | 1.07% | 1,204,891 | SH |
| 28 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $33.0M | 0.94% | 7,915,567 | SH |
| 29 | XENCOR INC | XNCR | 98401F105 | $29.6M | 0.85% | 2,452,138 | SH |
| 30 | ENTRADA THERAPEUTICS INC | TRDA | 29384C108 | $28.9M | 0.83% | 2,287,500 | SH |
| 31 | ALX ONCOLOGY HOLDINGS INC | ALXO | 00166B105 | $26.1M | 0.75% | 13,011,849 | SH |
| 32 | ARVINAS HOLDING CO LLC | ARVN | 04335A105 | $25.3M | 0.72% | 2,387,461 | SH |
| 33 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $24.9M | 0.71% | 1,789,617 | SH |
| 34 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $21.5M | 0.62% | 2,053,233 | SH |
| 35 | ALECTOR INC | ALEC | 014442107 | $21.5M | 0.62% | 10,000,000 | SH |
| 36 | MBX BIOSCIENCES INC | MBX | 55287L101 | $19.4M | 0.56% | 650,000 | SH |
| 37 | SILENCE THERAPEUTICS PLC | SLN | 82686Q101 | $16.0M | 0.46% | 3,033,560 | SH |
| 38 | LIQUIDIA TECHNOLOGIES INC | LQDA | 53635D202 | $15.2M | 0.44% | 403,048 | SH |
| 39 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $14.0M | 0.40% | 1,647,752 | SH |
| 40 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $11.0M | 0.32% | 738,383 | SH |
| 41 | UROGEN PHARMA LTD | URGN | M96088105 | $7.3M | 0.21% | 405,365 | SH |
| 42 | MONOPAR THERAPEUTICS INC | MNPR | 61023L207 | $7.2M | 0.21% | 132,103 | SH |
| 43 | CONTEXT THERAPEUTICS INC | CNTX | 21077P108 | $7.0M | 0.20% | 2,682,696 | SH |
| 44 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $6.8M | 0.19% | 140,411 | SH |
| 45 | CULLINAN THERAPEUTICS INC | CGEM | 230031106 | $5.8M | 0.17% | 406,786 | SH |
| 46 | KORRO BIO INC | KRRO | 500946108 | $4.7M | 0.13% | 416,301 | SH |
| 47 | LEONABIO INC | LONA | 04746L203 | $4.7M | 0.13% | 464,398 | SH |
| 48 | UPSTREAM BIO INC | UPB | 91678A107 | $1.6M | 0.05% | 181,063 | SH |
| 49 | VISTAGEN THERAPEUTICS INC | VTGN | 92840H400 | $1.5M | 0.04% | 2,676,580 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $3.50B | 49 | 0001214659-26-006367 |
| 2025-12-31 | 2026-02-17 | $3.02B | 43 | 0001214659-26-001871 |
| 2025-09-30 | 2025-11-17 | $2.03B | 40 | 0001214659-25-016751 |